Treatments:Diabetes
From Proteopedia
(Difference between revisions)
| (3 intermediate revisions not shown.) | |||
| Line 2: | Line 2: | ||
<tr> | <tr> | ||
<td style="width:25%; vertical-align:top;border-width:1px;"> | <td style="width:25%; vertical-align:top;border-width:1px;"> | ||
| - | =====Insulin===== | + | =====[[Insulin]]===== |
*[[Lantus]] - Generic: [[Insulin glargine]] | *[[Lantus]] - Generic: [[Insulin glargine]] | ||
*[[NovoLog]] - Generic: [[Insulin aspart]] | *[[NovoLog]] - Generic: [[Insulin aspart]] | ||
| Line 15: | Line 15: | ||
=====[[Glucagon-like peptide 1 receptor|Glucagon-like peptide-1]] (GLP-1) agonist===== | =====[[Glucagon-like peptide 1 receptor|Glucagon-like peptide-1]] (GLP-1) agonist===== | ||
* [[Victoza]] - Generic: [[Liraglutide]] | * [[Victoza]] - Generic: [[Liraglutide]] | ||
| + | * [[Ozempic]] - Generic: [[Semaglutide]] | ||
| + | |||
=====Mechanism is not completely understood===== | =====Mechanism is not completely understood===== | ||
*[[Metformin]] - Generic: [[N,N-dimethylbiguanide]] | *[[Metformin]] - Generic: [[N,N-dimethylbiguanide]] | ||
| + | =====Inhibitors of the sodium glucose co-transporter-2 (SGLT-2)===== | ||
| + | *[[Empagliflozin]] - Generic: Jardiance | ||
| + | *[[Canagliflozin]] | ||
| + | *[[Dapagliflozin]] | ||
| + | |||
</td> | </td> | ||
</tr> | </tr> | ||
</table> | </table> | ||
Current revision
Insulin
Dipeptidyl peptidase IV Inhibitor
Peroxisome Proliferator-Activated Receptor Agonist
Glucagon-like peptide-1 (GLP-1) agonist
Mechanism is not completely understood
Inhibitors of the sodium glucose co-transporter-2 (SGLT-2)
|
Proteopedia Page Contributors and Editors (what is this?)
Alexander Berchansky, David Canner, Michal Harel, Karsten Theis
